Kyprolis is a product of Amgen’s subsidiary Onyx Pharmaceuticals, which holds global development and commercialization rights to the product, excluding Japan. Onyx Pharmaceuticals president Pablo Cagnoni said: "Achieving
The new indication for Eylea includes macular edema following branch retinal vein occlusion (BRVO) in addition to the previously-approved indication of macular edema secondary to central retinal vein
Acceliant platforms offer smooth execution of clinical data management activities such as database design, UAT and several report formats for business intelligence. These platforms give Lupin a collaborative
A calcimimetic agent administered intravenously, AMG 416 binds to and activates the calcium-sensing receptor on the parathyroid gland, thereby reducing serum intact PTH levels. The randomized, active-controlled, double-blind,
The company’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases. According to the company, this development allows the generation of a
In the trial, eribulin showed a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, the primary endpoint of the study. The company said that
The drug is also indicated to treat pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. Owned by Actavis, Avycaz is a combination of a
Teva’s CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release hydrocodone designed to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative
The approval was on based data from the EDITION clinical trial program, which included a series of international Phase III trials evaluating the efficacy and safety of Toujeo
The three-year deal will see both companies jointly develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR?). According to AstraZeneca, RORy helps to convert a population of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.